Organovo (ONVO) Stock Price, News & Analysis

Company Overview

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California.

Key Stats

• Today's Range: $1.62 to $1.80
• 50-Day Range: $1.66 to $15.24
• 52-Week Range: $1.62 to $21.96
• Volume: 1.15 million shs
• Average Volume: 658,776 shs
• Market Capitalization: $2.82 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Organovo Stock Analysis - MarketRank™

Organovo scored higher than 18% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Organovo.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Organovo are expected to grow in the coming year, from ($0.77) to ($0.75) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Organovo is -1.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Organovo is -1.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Organovo has a P/B Ratio of 83.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.31% of the float of Organovo has been sold short.

Short Interest Ratio / Days to Cover

Organovo has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Organovo has recently decreased by 95.93%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Organovo does not currently pay a dividend.

Dividend Growth

Organovo does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.31% of the float of Organovo has been sold short.

Short Interest Ratio / Days to Cover

Organovo has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Organovo has recently decreased by 95.93%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.94

News Sentiment

Organovo has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Organovo this week, compared to 1 article on an average week.

Search Interest

Only 1 people have searched for ONVO on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.

MarketBeat Follows

2 people have added Organovo to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Organovo insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.72% of the stock of Organovo is held by insiders.

Percentage Held by Institutions

Only 8.23% of the stock of Organovo is held by institutions.

ONVO Stock Analysis - Frequently Asked Questions

How have ONVO shares performed this year?

Organovo's stock was trading at $5.5188 at the start of the year. Since then, ONVO shares have decreased by 69.9% and is now trading at $1.66.
View the best growth stocks for 2025 here.

How were Organovo's earnings last quarter?

Organovo Holdings, Inc. (NASDAQ:ONVO) announced its quarterly earnings data on Wednesday, February, 19th. The medical research company reported ($2.28) earnings per share for the quarter, topping the consensus estimate of ($2.52) by $0.24. The medical research company earned $0.02 million during the quarter, compared to analyst estimates of $0.05 million. Organovo had a negative trailing twelve-month return on equity of 346.26% and a negative net margin of 10,151.64%.

When did Organovo's stock split?

Organovo shares reverse split on the morning of Friday, March 21st 2025. The 1-12 reverse split was announced on Wednesday, March 19th 2025. The number of shares owned by shareholders was adjusted after the market closes on Thursday, March 20th 2025. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

How do I buy shares of Organovo?

Shares of ONVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Organovo own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Organovo investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), NIO (NIO), Brainstorm Cell Therapeutics (BCLI), AST SpaceMobile (ASTS) and Virgin Galactic (SPCE).

Company Calendar

• Last Earnings: 2/19/2025
• Today: 4/13/2025
• Next Earnings (Estimated): 5/30/2025
• Fiscal Year End: 3/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ONVO
• CIK: 1497253
• Web: www.organovo.com
• Phone: (858) 224-1000
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($10.20)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-14,670,000.00
• Net Margins: -10,151.64%
• Pretax Margin: -10,150.00%
• Return on Equity: -346.26%
• Return on Assets: -187.53%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.72
• Quick Ratio: 1.72

Sales & Book Value

• Annual Sales: $122,000.00
• Price / Sales: 23.14
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.02 per share
• Price / Book: 83.00

Miscellaneous

• Outstanding Shares: 1,701,000
• Free Float: 14,794,000
• Market Cap: $2.82 million
• Optionable: Optionable
• Beta: 1.13